Emerging treatments in the management of bipolar disorder -focus on risperidone long acting injection

Wissam El-Hage (1) , Simon Surguladze (2)

1 iBraiN - Imaging, Brain & Neuropsychiatry
2 King‘s College London

Bipolar disorder is a lifelong psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharma-cology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients' perspective and attitudes to long-acting injections will also be discussed.

Mots clés: second generation; antipsychotics; patient attitudes; lithium; valproate; monotherapy

Domaines: Psychiatrie et santé mentale

Wissam El-Hage, Simon Surguladze. Emerging treatments in the management of bipolar disorder -focus on risperidone long acting injection. Neuropsychiatric Disease and Treatment, 2010, pp.6 - 455. ⟨10.2147/NDT.S7608⟩. ⟨hal-02524330⟩